Source - RNS
RNS Number : 1458O
LiDCO Group Plc
01 February 2019
 

LiDCO Group Plc

("LiDCO" or the "Company")

 

Block Listing Review

 

LiDCO Group Plc (AIM: LID), the hemodynamic monitoring company, announces the following update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies in respect of its block listing of ordinary shares of 0.5 pence each ("Ordinary Shares").

 

Name of company

LiDCO Group Plc

Names of the schemes

LiDCO Group Plc Executive Share Option Scheme adopted on 6 June 2001 comprising Part A (Approved.), Part B (Unapproved), and Part C (Incentive Stock Options), the LiDCO Group Plc Enterprise Management Incentive Scheme 2002, the LiDCO Group Plc Unapproved Share Option Plan 2005, the LiDCO Group plc Share Option Plan 2013 formerly called the LiDCO Group Plc Enterprise Management Incentive Scheme 2013, and the LIDCO Group Plc Consultants Share Option Scheme 2003

Period of return

From 1 August 2018 to 31 January 2019

Number and class of securities not issued under the schemes

2,895,396 Ordinary Shares

Number of securities issued under the schemes during the period

Nil

Balance under the schemes of securities not yet issued at the end of the period

2,895,396 Ordinary Shares

Number and class of securities originally admitted and the date of admission

3,200,000 Ordinary Shares on 31 January 2014

 

 

For further information, please contact:

 

LiDCO Group Plc

www.lidco.com

Matthew Sassone (CEO)

Tel: +44 (0)20 7749 1500

Jill McGregor  (CFO)

 

 

 

finnCap

Tel: +44 (0)20 7220 0500

Geoff Nash / Emily Watts  (Corporate Finance)

 

Andrew Burdis (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRBGGDBBDDBGCU